# Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation

> **NCT02499237** · PHASE4 · COMPLETED · sponsor: **424 General Military Hospital** · enrollment: 57 (actual)

## Conditions studied

- Postmenopausal Osteoporosis

## Interventions

- **DRUG:** Denosumab
- **DRUG:** Zoledronic acid

## Key facts

- **NCT ID:** NCT02499237
- **Lead sponsor:** 424 General Military Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2018-11
- **Final completion:** 2018-11-26
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2019-03-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02499237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02499237, "Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02499237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*